O
RNAM

OrbiMed’s Avidity Biosciences RNAM Stock Holding History

OrbiMed’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-619,530
Closed -$44.7M – 126
2025
Q4 		$44.7M Sell
619,530
-1,019,356
-62% -$65.8M 0.91% 34
2025
Q3 		$71.4M Sell
1,638,886
-174,000
-10% -$7.03M 1.68% 16
2025
Q2 		$51.5M Hold
1,812,886
– – 1.29% 23
2025
Q1 		$53.5M Buy
1,812,886
+700,000
+63% +$21.8M 1.28% 25
2024
Q4 		$32.4M Buy
1,112,886
+68,081
+7% +$2.85M 0.67% 43
2024
Q3 		$48M Buy
1,044,805
+338,330
+48% +$14.7M 0.87% 33
2024
Q2 		$28.9M Sell
706,475
-287,625
-29% -$8.25M 0.57% 48
2024
Q1 		$25.4M Buy
+994,100
New +$15.6M 0.46% 58
2020
Q4 		– Sell
-63,860
Closed -$1.8M – 159
2020
Q3 		$1.8M Sell
63,860
-136,140
-68% -$3.93M 0.02% 136
2020
Q2 		$5.65M Buy
+200,000
New +$5.77M 0.08% 117

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $158M AUM

OrbiMed's RNAM Position: Q1 2026 in Review

OrbiMed sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 619,530 shares — an estimated $44.7M sold.

OrbiMed first reported a position in RNAM in Q2 2020 and held it in 10 quarters. The position peaked at $71.4M in Q3 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • OrbiMed reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • OrbiMed sold 619,530 Avidity Biosciences shares in Q1 2026, an estimated $44.7M.
  • OrbiMed first reported a position in Avidity Biosciences in Q2 2020 and held it in 10 quarters.
  • OrbiMed's Avidity Biosciences position peaked at $71.4M in Q3 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.